| Company Name | Chugai Pharma Taiwan Ltd. |
|---|---|
| Protocol Number | TW-TCZ-14001(E)~14004(E) |
| Title of Study | Efficacy and safety evaluation of tocilizumab monotherapy in Taiwan population |
| Primary Objective | -To demonstrate non-inferiority of tocilizumab monotherapy to tocilizumab 8 mg/kg combine DMARDs -Sub study: observation study of tocilizumab 4 mg/kg -To evaluate safety profile of long term treatment |
| Number of Sites | 23 |
| Period of Study | From：July 2015 to：June 2018 |
| Number of Patients | 480人 |
| IRB Approval Date | 長庚 May 05, 2015; 嘉基 May 28, 2015; other IRBs not yet |
| Publication Plan / Date | 2017 |
